Powered by

SOFIE And University Clinic Heidelberg Sign License Agreement For Theranostics That Target Cancer Associated Fibroblasts

Jun 21, 2019 - PR Newswire

PR Newswire

 SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics ("theranostics") that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells. These quinoline-based compounds that act as fibroblast activation-protein inhibitors ("FAPI") are also the subject of the Journal of ...